

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

*(Use as many sheets as necessary)*

Sheet	1	of	1
-------	---	----	---

Application Number	10/665,936
Filing Date	August 18, 2003
First Named Inventor	Chu et al.
Art Unit	Unknown 1615
Examiner Name	UnknownSKennedy
Attorney Docket Number	P1768 (MEDT/0024)


[illegible][illegible]

Examiner Signature	/Sharon Kennedy/	Date Considered	05/24/2006
-----------------------	------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/665,936
		Filing Date	August 18, 2003
		First Named Inventor	Chu et al.
		Art Unit	Unknown 1615
		Examiner Name	Unknown SKennedy
Sheet 1 of 3		Attorney Docket Number	P1768 (MEDT/0024)

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
SK	1	US- 2002/0065546	05/30/2002	Machan et al.	
	2	US- 5,538,504	07/23/1996	SciMed Life Systems, Inc.	
	3	US- 5,670,161	09/23/1997	Healy et al.	
	4	US- 5,834,449	12/10/1998	The Research Foundation of State University of New York; Washington University	
	5	US- 6,159,239	12/12/2000	Prodesco, Inc.	
	6	US- 6,190,353	02/20/2001	TransVascular, Inc.	
	7	US- 6,302,870	10/16/2001	Precision Vascular Systems, Inc.	
	8	US- 6,344,035	02/05/2002	Surmodics, Inc.	
	9	US- 6,348,050	02/19/2002	Medtronic, Inc.	
	10	US- 6,364,903	04/02/2002	Meadox Medicals, Inc.	
	11	US- 6,368,346	04/09/2002	American Medical Systems, Inc.	
	12	US- 6,371,970	04/16/2002	Incept LLC	
	13	US- 6,376,742	04/23/2002	Zdrahala et al.	
	14	US- 6,387,121	05/14/2002	Inflow Dynamics Inc.	
	15	US- 6,451,373	09/17/2002	Advanced Cardiovascular Systems, Inc.	
	16	US- 6,506,410	01/14/2003	Kong Kook Pharmaceutical Co., Ltd.	
	17	US- 6,514,515	02/04/2003	Tepha, Inc.	
SK	18	US- 6,531,154	03/11/2003	Brown University Research Foundation	


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> *Number <sup>4</sup> *Kind Code <sup>5</sup> (if known)				
SK	1	WO-02/15824-A2	02/28/2002	Kensey Nash Corporation		

Examiner Signature	/Sharon Kennedy/	Date Considered	05/24/2006
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/665,936		
		Filing Date	September 19, 2003		
		First Named Inventor	Chu et al.		
		Art Unit	Unknown		
		Examiner Name	Unknown		
Sheet	2	of	3	Attorney Docket Number	P1768 (MEDT/0024)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SK	1	"Beta-Blockers (Beta-Adrenergic Blocking Drugs)." <u>Texas Heart Institute Heart Information Center</u> . 18 March 2003 < <a href="http://www.tmc.edu/thi/betameds.html">http://www.tmc.edu/thi/betameds.html</a> >.	
SK	2	"Beta Blockers." <u>Cardiac Consultants</u> . 18 March 2003 < <a href="http://www.cardiacconsultants.com/beta.htm">http://www.cardiacconsultants.com/beta.htm</a> >.	
SK	3	"Beta Blockers (Beta-Adrenergic Blockers, Beta 1 Blockers, Beta 2 Blockers, B-Blockers)." <u>HeartCenterOnline</u> . 18 March 2003 < <a href="http://www.heartcenteronline.com/myheartdr/common/articles.cfm?ARTID=331">http://www.heartcenteronline.com/myheartdr/common/articles.cfm?ARTID=331</a> >.	
SK	4	"beta-blocker." <u>Bartleby.com</u> . 18 March 2003 < <a href="http://www.bartleby.com/65/be/beta-b.html">http://www.bartleby.com/65/be/beta-b.html</a> >.	
SK	5	Slaiby, Jeffrey M. et al. "Expansion of aortic aneurysms is reduced by propranolol in a hypertensive rat model." <u>Journal of Vascular Surgery</u> . 21 January 2002 < <a href="http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&amp;searchDBfor=art&amp;a...">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&amp;searchDBfor=art&amp;a...</a> >.	
SK	6	Vine, N. et al. "Metalloproteinases in degenerative aortic disease." <u>Clinical Science</u> 1991, 81: 233-239.	
SK	7	Goodman, Louis Sanford and Albert Gilman. <u>The Pharmacological Basis of Therapeutics</u> . New York: McGraw-Hill, 2001.	
SK	8	Jackson, Edwin K. "Renin and Angiotensin." 809-835.	
SK	9	Liao, Shixiong et al. "Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors." <u>Journal of Vascular Surgery</u> . May 2001, 33, No. 5: 1057-1064.	
SK	10	Chaikof, Elliot L. et al. "Biomaterials and Scaffolds in Reporative Medicine." <u>Annals New York Academy of Sciences</u> 2002, 961: 96-105.	


Examiner Signature	/Sharon Kennedy/	Date Considered	05/24/2006
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/665,936
Filing Date	September 19, 2003
First Named Inventor	Chu et al.
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	PA1768 (MEDT/0024)

Sheet	3	of	3
-------	---	----	---

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SK	11	Griffith, Linda G. "Emerging Design Principles In Biomaterials and Scaffolds or Tissue Engineering." <u>Annals New York Academy of Sciences</u> 2002, 961: 83-95.	
SK	12	Ochoa, Erin R. et al. "An Overview of the Pathology and Approaches to Tissue Engineering." <u>Annals New York Academy of Sciences</u> 2002, 979: 10-26.	

Examiner Signature	/Sharon Kennedy/	Date Considered	05/24/2006
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.